The hematologic and lymphatic system spectra of anti-PD-L1 drugs varied substantially, with 24 PTs significantly associated with the atezolizumab treatment, ranging from agranulocytosis (ROR025: 1.11) to myelosuppression (ROR025: 13.20). This evidence concerns the gene CD274 and Absence of circulating granulocytes.